0.156
10.64%
+0.015
After Hours:
.1575
0.0015
+0.96%
Onconetix Inc stock is currently priced at $0.156, with a 24-hour trading volume of 15.72M.
It has seen a +10.64% increased in the last 24 hours and a +25.91% rose in the past month.
The chart indicates a potential bullish trend, as the stock is above the $0.1374 pivot point. If it approaches the $0.1596 resistance level, significant changes may occur.
Previous Close:
$0.141
Open:
$0.185
24h Volume:
15.72M
Market Cap:
$3.48M
Revenue:
-
Net Income/Loss:
$-18.28M
P/E Ratio:
-
EPS:
-
Net Cash Flow:
$-12.15M
1W Performance:
+47.17%
1M Performance:
+25.91%
6M Performance:
+0.00%
1Y Performance:
+0.00%
Onconetix Inc Stock (ONCO) Company Profile
Name
Onconetix Inc
Sector
Industry
Phone
513 620 4101
Address
201 East Fifth Street, Suite 1900, Cincinnati
Onconetix Inc Stock (ONCO) Latest News
Company’s Banking Stock: Dissecting a -16.27% Quarterly Revenue Decline Amid Growth - The InvestChronicle
The InvestChronicle
Onconetix Inc (NASDAQ: ONCO) Is A Blank Check For Growth – Stocks Register - Stocks Register
Stocks Register
Onconetix (NASDAQ:ONCO) Shares Down 5.3% - Defense World
Defense World
Onconetix appoints Dr. Ajit Singh to board of directors - indica News - indica News
indica News
Onconetix Announces Appointment of Seasoned Biotech Executives Dr. Ajit Singh and Dr. Thomas Meier to Its Board of Directors
GlobeNewswire Inc.
Onconetix Welcomes Ajit Singh to Board Amidst Leadership Changes - TipRanks.com - TipRanks
TipRanks
Onconetix Inc Stock (ONCO) Financials Data
Onconetix Inc (ONCO) Net Income 2024
ONCO net income (TTM) was -$18.28 million for the quarter ending September 30, 2023, a -60.25% decrease year-over-year.
Onconetix Inc (ONCO) Cash Flow 2024
ONCO recorded a free cash flow (TTM) of -$12.15 million for the quarter ending September 30, 2023, a -85.46% decrease year-over-year.
Onconetix Inc (ONCO) Earnings per Share 2024
ONCO earnings per share (TTM) was -$1.08 for the quarter ending September 30, 2023, a +1.40% growth year-over-year.
About Onconetix Inc
Blue Water Biotech, Inc., a biotechnology and pharmaceutical company, focuses on developing and commercializing transformational therapies to address health challenges worldwide. The company owns ENTADFI, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia. It is also developing a streptococcus pneumoniae vaccine candidate, which is designed to prevent infectious middle ear infections in children, and prevention of pneumonia in the elderly; and universal flu vaccine that provide protection from all virulent strains in addition to licensing a novel norovirus S&P nanoparticle versatile virus-like particle vaccine platform from Cincinnati Children's to develop vaccines for multiple infectious diseases, including Marburg and monkeypox, and others. The company was formerly known as Blue Water Vaccines, Inc. and changed its name to Blue Water Biotech, Inc. in April 2023. Blue Water Biotech, Inc. was incorporated in 2018 and is headquartered in Cincinnati, Ohio.
Cap:
|
Volume (24h):